CytoMed Therapeutics Ltd
NASDAQ:GDTC
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| SG |
C
|
CytoMed Therapeutics Ltd
NASDAQ:GDTC
|
12.5m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
387.4B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
201.5B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
186.3B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.8B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.1B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -230 800 561.6% |
| 30th Percentile | -1.2% |
| Median | 2.9% |
| 70th Percentile | 9% |
| Max | 5 696 822.3% |
Other Profitability Ratios
CytoMed Therapeutics Ltd
Glance View
CytoMed Therapeutics Ltd. operates as a biopharmaceutical company. The company employs 27 full-time employees The company went IPO on 2023-04-14. The firm is focused on harnessing its licensed proprietary technologies to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies, as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. The company is developing three product candidates: CTM-N2D, iPSC-gdNKT and CTM-GDT. CTM-N2D is its lead product candidate, and it consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. Its second product candidate, iPSC-gdNKT, utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. Its third product candidate, CTM-GDT, consists of expanded allogeneic gamma delta T cells.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for CytoMed Therapeutics Ltd is -1 629.1%, which is above its 3-year median of -2 625.1%.
Over the last 6 months, CytoMed Therapeutics Ltd’s Net Margin has increased from -3 621.2% to -1 629.1%. During this period, it reached a low of -3 621.2% on Dec 31, 2024 and a high of -1 629.1% on Jul 30, 2025.
